<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Alcon Inc</title>
	<atom:link href="http://www.stockbloghub.com/tag/alcon-inc/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Sun, 20 May 2012 20:27:31 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(WMGI) Wright Medical Group Gets a New CEO</title>
		<link>http://www.stockbloghub.com/2011/09/21/wmgi-wright-medical-group-gets-a-new-ceo/83685</link>
		<comments>http://www.stockbloghub.com/2011/09/21/wmgi-wright-medical-group-gets-a-new-ceo/83685#comments</comments>
		<pubDate>Wed, 21 Sep 2011 15:09:26 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[ACL]]></category>
		<category><![CDATA[Alcon Inc]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Smith & Nephew Plc]]></category>
		<category><![CDATA[SNN]]></category>
		<category><![CDATA[Stryker Corporation]]></category>
		<category><![CDATA[SYK]]></category>
		<category><![CDATA[WMGI]]></category>
		<category><![CDATA[Wright Medical Group Inc]]></category>
		<category><![CDATA[Zimmer Holdings Inc]]></category>
		<category><![CDATA[ZMH]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=83685</guid>
		<description><![CDATA[International orthopedic devices company Wright Medical Group (WMGI) recently reported that its Board of Directors chose Mr. Robert J. Palmisano as President and CEO, starting from September 17, 2011. Mr. David D. Stevens, who was interim President and CEO, will remain Chairman of the Board. Mr. Palmisano has notable expertise managing important listed medtech companies. Until recently, he was President and CEO of ev3. During his 2-year stint there, the market capitalization of ev3 jumped more than three fold, from about $800 million in April 2008 to $2,600 million in July 2010. Mr. Palmisano was President and CEO of IntraLase Corp. prior to joining ev3. Still earlier, he was President and CEO of MacroChem Corporation. He also served as President and CEO of Summit Technology Inc. until it was taken ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/21/wmgi-wright-medical-group-gets-a-new-ceo/83685/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABV) Company News for December 15, 2010 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2010/12/15/abv-company-news-for-december-15-2010-corporate-summary/62404</link>
		<comments>http://www.stockbloghub.com/2010/12/15/abv-company-news-for-december-15-2010-corporate-summary/62404#comments</comments>
		<pubDate>Wed, 15 Dec 2010 21:04:02 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Beverages - Brewers]]></category>
		<category><![CDATA[Consumer Goods]]></category>
		<category><![CDATA[ABV]]></category>
		<category><![CDATA[ACL]]></category>
		<category><![CDATA[Agrium Inc.]]></category>
		<category><![CDATA[AGU]]></category>
		<category><![CDATA[Alcon Inc]]></category>
		<category><![CDATA[Companhia de Bebidas Das Americas (AMBEV)]]></category>
		<category><![CDATA[DYN]]></category>
		<category><![CDATA[Dynegy Inc.]]></category>
		<category><![CDATA[Goldman Sachs Group]]></category>
		<category><![CDATA[GS]]></category>
		<category><![CDATA[Icahn Enterprises L.P.]]></category>
		<category><![CDATA[IEP]]></category>
		<category><![CDATA[Joy Global]]></category>
		<category><![CDATA[JOYG]]></category>
		<category><![CDATA[JPM]]></category>
		<category><![CDATA[JPMorgan Chase & Company]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[R]]></category>
		<category><![CDATA[Ryder System]]></category>
		<category><![CDATA[T. Rowe Price Group]]></category>
		<category><![CDATA[TROW]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=62404</guid>
		<description><![CDATA[• Joy Global (NASDAQ:JOYG) reported fiscal fourth quarter earnings of $1.39, ahead of the Zacks Consensus Estimate of $1.16, on revenues of $1.05 billion that topped the Zacks Consensus Estimate of $925.0 million. The firm provided upside 2011 guidance of $5.00-$5.30, above the Zacks Consensus Estimate of $4.17 • Novartis (NYSE:NVS) plans to accuire 22% of Alcon (NYSE:ACL), for $168 per share, or $12.9 billion • Agrium (NYSE:AGU) will sell their majority interest in AWB Ltd to Cargill for $870 million • Icahn Enterprises (NYSE:IEP) plans to buy Dynegy (NYSE:DYN) for $5.50 per share, or $665.0 million • Goldman Sachs (NYSE:GS) initiated coverage on T. Rowe Price (NASDAQ:TROW) from &#8220;neutral&#8221; rating to placing the company on its Conviction Buy list, upgrading  price target from $55 to $80 • JP Morgan (NYSE:JPM) upgraded AmBev (NYSE:ABV) from &#8220;neutral&#8221; ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/12/15/abv-company-news-for-december-15-2010-corporate-summary/62404/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(JNJ) Pharma &amp; Biotech Industry Outlook &#8211; November 2010 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2010/11/15/jnj-pharma-biotech-industry-outlook-november-2010-industry-outlook/58687</link>
		<comments>http://www.stockbloghub.com/2010/11/15/jnj-pharma-biotech-industry-outlook-november-2010-industry-outlook/58687#comments</comments>
		<pubDate>Mon, 15 Nov 2010 18:56:40 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[ACL]]></category>
		<category><![CDATA[Alcon Inc]]></category>
		<category><![CDATA[Alkermes]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[KG]]></category>
		<category><![CDATA[King Pharmaceuticals Inc.]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MDCO]]></category>
		<category><![CDATA[Medicines Company]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[ONXX]]></category>
		<category><![CDATA[Onyx Pharmaceuticals Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[VIVUS Inc]]></category>
		<category><![CDATA[VVUS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=58687</guid>
		<description><![CDATA[With 2010 coming to an end, the pharmaceutical industry continues to witness major challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition and limited late-stage catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. According to IMS Health, this is the main reason global pharmaceutical market growth will be restricted to the mid-single digits (5-8%) through 2014. Over the next five years, products that currently generate more than $142 billion in sales are expected to face generic competition Incorporatedluding Lipitor, Plavix and Zyprexa. In fact, 2011 itself will see products worth more than $30 billion losing patent protection. This includes products like Lipitor, Plavix, Zyprexa and Levaquin. According to IMS Health, these products generated more than $17 billion ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/11/15/jnj-pharma-biotech-industry-outlook-november-2010-industry-outlook/58687/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ACL) A Food Fight Over Nutraceuticals</title>
		<link>http://www.stockbloghub.com/2010/10/18/acl-a-food-fight-over-nutraceuticals/55606</link>
		<comments>http://www.stockbloghub.com/2010/10/18/acl-a-food-fight-over-nutraceuticals/55606#comments</comments>
		<pubDate>Tue, 19 Oct 2010 05:02:57 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACL]]></category>
		<category><![CDATA[Alcon Inc]]></category>
		<category><![CDATA[HJ Heinz Company]]></category>
		<category><![CDATA[HNZ]]></category>
		<category><![CDATA[Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[PEP]]></category>
		<category><![CDATA[Pepsico]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=55606</guid>
		<description><![CDATA[by Tony D’Altorio, Investment U Research Monday, October 18, 2010 At first glance, the food and drug industries have very little in common. One is a relatively slow and safe business, the other a high-risk, high-reward venture. Yet these days, they seem to be moving in a common direction… straight towards the clinical nutrition and nutraceuticals business. Broadly speaking, clinical nutrition and nutraceuticals offer a wide range of products. They make foodstuffs and non-prescription medications that slow or prevent illnesses. Basically, nutraceuticals take the fortified food market – worth an expected $175 billion worldwide this year – up to the next level. About five years ago, energy drinks mainstreamed the sector, but it still has a lot more to grow. Knowing that, who can blame multinational food companies and the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/10/18/acl-a-food-fight-over-nutraceuticals/55606/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABT) Pharma and Biotech Industry Outlook &#8211; July 2010 &#8211; Analyst Interviews</title>
		<link>http://www.stockbloghub.com/2010/07/26/abt-pharma-and-biotech-industry-outlook-july-2010-analyst-interviews/44204</link>
		<comments>http://www.stockbloghub.com/2010/07/26/abt-pharma-and-biotech-industry-outlook-july-2010-analyst-interviews/44204#comments</comments>
		<pubDate>Mon, 26 Jul 2010 14:58:05 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[ABII]]></category>
		<category><![CDATA[Abraxis Bioscience Inc]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[ACL]]></category>
		<category><![CDATA[ACOR]]></category>
		<category><![CDATA[Acorda Therapeutics Inc]]></category>
		<category><![CDATA[Alcon Inc]]></category>
		<category><![CDATA[Alkermes]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MDCO]]></category>
		<category><![CDATA[Medicines Company]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[ONXX]]></category>
		<category><![CDATA[Onyx Pharmaceuticals Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=44204</guid>
		<description><![CDATA[The pharmaceutical industry has witnessed major changes over the past few quarters, with performance being affected by factors like sluggish prescription trends, intensifying generic competition and limited late-stage catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. According to IMS Health, this is the main reason global pharmaceutical market growth will be restricted to the mid-single digits (5-8%) through 2014. Over the next five years, products that currently generate more than $142 billion in sales are expected to face generic competition Incorporatedluding Lipitor, Plavix and Zyprexa. At the same time, new products are not expected to generate the same level of sales as products losing patent protection. With revenue growth stalling or slowing down, companies have been resorting to cost-cutting ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/07/26/abt-pharma-and-biotech-industry-outlook-july-2010-analyst-interviews/44204/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABT) Pharma and Biotech Industry Outlook &#8211; July 2010 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2010/07/20/abt-pharma-and-biotech-industry-outlook-july-2010-industry-outlook/44146</link>
		<comments>http://www.stockbloghub.com/2010/07/20/abt-pharma-and-biotech-industry-outlook-july-2010-industry-outlook/44146#comments</comments>
		<pubDate>Wed, 21 Jul 2010 03:08:56 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[ABII]]></category>
		<category><![CDATA[Abraxis Bioscience Inc]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[ACL]]></category>
		<category><![CDATA[ACOR]]></category>
		<category><![CDATA[Acorda Therapeutics Inc]]></category>
		<category><![CDATA[Alcon Inc]]></category>
		<category><![CDATA[Alkermes]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Inc.]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MDCO]]></category>
		<category><![CDATA[Medicines Company]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[ONXX]]></category>
		<category><![CDATA[Onyx Pharmaceuticals Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=44146</guid>
		<description><![CDATA[The pharmaceutical industry has witnessed major changes over the past few quarters, with performance being affected by factors like sluggish prescription trends, intensifying generic competition and limited late-stage catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. According to IMS Health, this is the main reason global pharmaceutical market growth will be restricted to the mid-single digits (5-8%) through 2014. Over the next five years, products that currently generate more than $142 billion in sales are expected to face generic competition Incorporatedluding Lipitor, Plavix and Zyprexa. At the same time, new products are not expected to generate the same level of sales as products losing patent protection. With revenue growth stalling or slowing down, companies have been resorting to cost-cutting ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/07/20/abt-pharma-and-biotech-industry-outlook-july-2010-industry-outlook/44146/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABT) Pharma &amp; Biotech Stock Review &#8211; April 2010 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2010/04/29/abt-pharma-biotech-stock-review-april-2010-industry-outlook/35472</link>
		<comments>http://www.stockbloghub.com/2010/04/29/abt-pharma-biotech-stock-review-april-2010-industry-outlook/35472#comments</comments>
		<pubDate>Thu, 29 Apr 2010 14:10:15 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[ACL]]></category>
		<category><![CDATA[ACOR]]></category>
		<category><![CDATA[Acorda Therapeutics Inc]]></category>
		<category><![CDATA[Alcon Inc]]></category>
		<category><![CDATA[Amgen Inc]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Inc.]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MannKind Corporation]]></category>
		<category><![CDATA[MDCO]]></category>
		<category><![CDATA[Medicines Company]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MIL]]></category>
		<category><![CDATA[Millipore Corporation]]></category>
		<category><![CDATA[MNKD]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[OSI Pharmaceuticals Inc]]></category>
		<category><![CDATA[OSIP]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=35472</guid>
		<description><![CDATA[The pharmaceutical industry has witnessed major changes over the past few quarters, with performance being affected by factors like sluggish prescription trends, intensifying generic competition and limited phase III catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. According to IMS Health, this is the main reason global pharmaceutical market growth will be restricted to the mid-single digits (5-8%) through 2014. Over the next five years, products that currently generate more than $142 billion in sales are expected to face generic competition Incorporatedluding Lipitor, Plavix and Zyprexa. At the same time, new products are not expected to generate the same level of sales as products losing patent protection. With revenue growth stalling or slowing down, companies have been resorting to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/29/abt-pharma-biotech-stock-review-april-2010-industry-outlook/35472/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ACL) Alcon Completes Product Deals</title>
		<link>http://www.stockbloghub.com/2010/03/31/acl-alcon-completes-product-deals/32393</link>
		<comments>http://www.stockbloghub.com/2010/03/31/acl-alcon-completes-product-deals/32393#comments</comments>
		<pubDate>Wed, 31 Mar 2010 20:14:13 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACL]]></category>
		<category><![CDATA[Advanced Micro Devices Inc.]]></category>
		<category><![CDATA[AGN]]></category>
		<category><![CDATA[Alcon Inc]]></category>
		<category><![CDATA[Allergan Inc.]]></category>
		<category><![CDATA[AMD]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=32393</guid>
		<description><![CDATA[Alcon, Inc. (ACL) recently announced that it has acquired rights to two topical eye care products, Durezol and Zyclorin, from Sirion Therapeutics, Inc. Alcon also said that it is evaluating options to acquire another product, Zirgan, which is approved for the treatment of acute herpetic keratitis or corneal ulcers. While Durezol is approved by the US Food and Drug Administration (FDA), Zyclorin is being developed for the treatment of dry eye and other ocular surface diseases. Alcon has rights for Zyclorin in all territories excluding Latin America. Alcon said that it will take charge of all marketing, promotion and sales of Durezol in the United States immediately. Durezol is approved for the treatment of inflammation and pain associated with eye surgery. This agreement is in-line with the company&#8217;s goal to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/31/acl-alcon-completes-product-deals/32393/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ACL) Alcon &#8211; Solid Growth Across All Segments &#8211; Novartis Wants to Acquire Alcon</title>
		<link>http://www.stockbloghub.com/2010/03/03/acl-alcon-solid-growth-across-all-segments-novartis-wants-to-acquire-alcon/29521</link>
		<comments>http://www.stockbloghub.com/2010/03/03/acl-alcon-solid-growth-across-all-segments-novartis-wants-to-acquire-alcon/29521#comments</comments>
		<pubDate>Wed, 03 Mar 2010 22:00:37 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACL]]></category>
		<category><![CDATA[Alcon Inc]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[NBY]]></category>
		<category><![CDATA[NovaBay Pharmaceuticals Inc]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=29521</guid>
		<description><![CDATA[Alcon (ACL) is delivering solid growth across all business segments and pays a dividend yield of 2.3%. Company Description Alcon is one of the world&#8217;s leading suppliers of eye care products. The company has three operating segments: Pharmaceutical, which develops glaucoma products, ocular anti-infectives, and ocular allergy products, Surgical, which serves cataract market with its Infiniti vision system and AcrySof intraocular lenses, and Consumer Eye Care, which sells contact lens care products, artificial tears, and ocular vitamins. Growth Story Alcon&#8217;s pharmaceutical and surgical segments continue to deliver steady revenue growth. In the fourth quarter, U.S. sales were up 10% thanks to improving demand for prescriptions and cataract procedures. International organic sales, driven by emerging markets, were up 7%. In addition, Alcon&#8217;s acquisition strategy should help drive long-term growth. The company ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/03/acl-alcon-solid-growth-across-all-segments-novartis-wants-to-acquire-alcon/29521/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ACL) Alcon Beats Earnings Expectations on Strong Revenues</title>
		<link>http://www.stockbloghub.com/2010/02/15/acl-alcon-beats-earnings-expectations-on-strong-revenues/27994</link>
		<comments>http://www.stockbloghub.com/2010/02/15/acl-alcon-beats-earnings-expectations-on-strong-revenues/27994#comments</comments>
		<pubDate>Mon, 15 Feb 2010 23:28:53 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACL]]></category>
		<category><![CDATA[Alcon Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=27994</guid>
		<description><![CDATA[Alcon Inc. (ACL) reported fourth quarter earnings of $1.61 per share, easily beating the Zacks Consensus Estimate of $1.50 and 14.2% above the year-ago earnings of $1.41. Full year earnings came in at $6.81, 10 cents above the Zacks Consensus Estimate and 13.5% above the year ago results. Net earnings increased mainly due to stronger-than-expected revenues and an improved market environment. Quarterly revenues increased 8.5% (including the impact of foreign exchange) to $1.7 billion. Full year revenues increased 6.3% (including the impact of foreign exchange) to $6.5 billion. All the revenue segments at Alcon put in a strong performance in the reported quarter. While pharmaceutical sales increased 12.3% to $679 million, surgical sales increased 7.9% to $828 million. Consumer sales grew 5.6% to $208 million. Meanwhile, revenues from emerging markets ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/02/15/acl-alcon-beats-earnings-expectations-on-strong-revenues/27994/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(RX) Pharma &amp; Biotech Stock Review &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2010/01/29/rx-pharma-biotech-stock-review-industry-outlook/26385</link>
		<comments>http://www.stockbloghub.com/2010/01/29/rx-pharma-biotech-stock-review-industry-outlook/26385#comments</comments>
		<pubDate>Sat, 30 Jan 2010 00:08:31 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Research Services]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[ACL]]></category>
		<category><![CDATA[ACOR]]></category>
		<category><![CDATA[Acorda Therapeutics Inc]]></category>
		<category><![CDATA[Alcon Inc]]></category>
		<category><![CDATA[Alkermes]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[IMS Health Inc.]]></category>
		<category><![CDATA[Inc.]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MannKind Corporation]]></category>
		<category><![CDATA[MDCO]]></category>
		<category><![CDATA[Medicines Company]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MNKD]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[RX]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=26385</guid>
		<description><![CDATA[The pharmaceutical industry has witnessed major changes over the past few quarters, with performance being affected by factors like sluggish prescription trends, intensifying generic competition and limited phase III catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. According to IMS Health (RX), this is the main reason global pharmaceutical market growth will be restricted to the mid-single digits through 2013. Over the next five years, products that currently generate about $137 billion in sales are expected to face generic competition Incorporatedluding Lipitor, Plavix and Seretide. At the same time, new products are not expected to generate the same level of sales as products losing patent protection. With revenue growth stalling or slowing down, companies have been resorting to cost-cutting ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/29/rx-pharma-biotech-stock-review-industry-outlook/26385/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ACL) Novartis&#8217; Purchase Offer Inadequate for Alcon</title>
		<link>http://www.stockbloghub.com/2010/01/21/acl-novartis-purchase-offer-inadequate-for-alcon/25675</link>
		<comments>http://www.stockbloghub.com/2010/01/21/acl-novartis-purchase-offer-inadequate-for-alcon/25675#comments</comments>
		<pubDate>Fri, 22 Jan 2010 01:17:37 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACL]]></category>
		<category><![CDATA[Alcon Inc]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=25675</guid>
		<description><![CDATA[Eye care company Alcon, Inc. (ACL) announced that its Independent Director Committee recently responded to Novartis AG’s (NVS) proposal to acquire its minority publicly traded shares. The Committee referred to the proposal as “grossly inadequate&#8221; and “fundamentally flawed&#8221;. Earlier this month, Novartis had announced that it intends to gain full ownership of Alcon. Novartis will initially complete its April 2008 agreement with Nestlé S.A. whereby it will acquire a majority stake (77%) in Alcon. Of this, the company has already acquired a 25% stake in 2008 for $10.4 billion. Novartis will be paying $28.1 billion for Nestlé’s remaining 52% stake in Alcon. Once this deal is completed in the second half of the year, Novartis is planning to acquire the remaining 23% minority stake. Each Alcon share will receive 2.8 ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/21/acl-novartis-purchase-offer-inadequate-for-alcon/25675/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ACL) Alcon Strengthens Product Pipeline</title>
		<link>http://www.stockbloghub.com/2010/01/20/acl-alcon-strengthens-product-pipeline/25460</link>
		<comments>http://www.stockbloghub.com/2010/01/20/acl-alcon-strengthens-product-pipeline/25460#comments</comments>
		<pubDate>Wed, 20 Jan 2010 22:46:05 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACL]]></category>
		<category><![CDATA[Advanced Micro Devices Inc.]]></category>
		<category><![CDATA[AGN]]></category>
		<category><![CDATA[Alcon Inc]]></category>
		<category><![CDATA[Allergan Inc.]]></category>
		<category><![CDATA[AMD]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=25460</guid>
		<description><![CDATA[Alcon, Inc. (ACL) continues to work on expanding its product portfolio. The company recently entered into an agreement with Sirion Therapeutics, Inc. for the purchase of rights to two topical eye care products, Durezol and Zirgan. Both products have been approved by the US Food and Drug Administration (FDA). The deal is scheduled to close in the first quarter of 2010. While Durezol is approved for the treatment of inflammation and pain associated with eye surgery, Zirgan is approved for the treatment of acute herpetic keratitis or corneal ulcers. Alcon also gained global rights, excluding Latin America, to pipeline candidate Zyclorin, which is being developed for the treatment of dry eye and other ocular surface diseases. This agreement is in-line with the company&#8217;s goal to expand its product portfolio and ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/20/acl-alcon-strengthens-product-pipeline/25460/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(NVS) Novartis Collaborates with GenVec on Hearing Loss Treatments</title>
		<link>http://www.stockbloghub.com/2010/01/20/nvs-novartis-collaborates-with-genvec-on-hearing-loss-treatments/25401</link>
		<comments>http://www.stockbloghub.com/2010/01/20/nvs-novartis-collaborates-with-genvec-on-hearing-loss-treatments/25401#comments</comments>
		<pubDate>Wed, 20 Jan 2010 18:34:07 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACL]]></category>
		<category><![CDATA[Alcon Inc]]></category>
		<category><![CDATA[GenVec Inc]]></category>
		<category><![CDATA[GNVC]]></category>
		<category><![CDATA[INCY]]></category>
		<category><![CDATA[Incyte Corporation]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=25401</guid>
		<description><![CDATA[Recently, Novartis (NVS) entered into a collaboration with GenVec (GNVC) for the development of treatments for hearing loss and balance disorders. Earlier, preclinical results have found strong potential in GenVec&#8217;s adenovector technology for the restoration of hearing and balance functions. Per the agreement, Novartis has acquired worldwide rights to the program, for which it has paid $5 million upfront. GenVec is also eligible to receive up to $213.6 million in the form of milestone payments and royalties on the sale of the drug. In addition, Novartis has purchased shares of GenVec worth $2 million. It will also provide funding to GenVec for conducting research programs for the development of additional adenovectors for hearing loss. Novartis is looking at strengthening its pipeline to compensate for the loss of revenues once several ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/20/nvs-novartis-collaborates-with-genvec-on-hearing-loss-treatments/25401/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ACL) What Nestle Wants Nestle Gets &#8211; And Right Now, Nestle Wants a Bigger Slice of the Pie</title>
		<link>http://www.stockbloghub.com/2010/01/18/acl-what-nestle-wants-nestle-gets-and-right-now-nestle-wants-a-bigger-slice-of-the-pie/25189</link>
		<comments>http://www.stockbloghub.com/2010/01/18/acl-what-nestle-wants-nestle-gets-and-right-now-nestle-wants-a-bigger-slice-of-the-pie/25189#comments</comments>
		<pubDate>Tue, 19 Jan 2010 00:21:09 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACL]]></category>
		<category><![CDATA[Alcon Inc]]></category>
		<category><![CDATA[Cadbury plc]]></category>
		<category><![CDATA[CBY]]></category>
		<category><![CDATA[KFT]]></category>
		<category><![CDATA[Kraft Foods Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=25189</guid>
		<description><![CDATA[by Tony Daltorio, Investment U Research Monday, January 18, 2010 It would take far too long to list the leading brands Nestle ADR (OTC: NSRGY) owns, considering that it’s the world’s biggest food corporation with operations in almost every country. Suffice it to say however, that you’ve probably purchased at least a few of their dairy products, bottled water, ice cream, pizza, pasta, soup, frozen foods, infant nutrition, adult nutrition, pet foods and of course, their chocolate at least once in your lifetime, if not every time you make a grocery run. And despite its enormous size, Nestle continues to experience real organic growth – like the 7.5% expansion it recorded in emerging markets from January through September last year, which helped offset losses elsewhere and resulted in an overall ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/18/acl-what-nestle-wants-nestle-gets-and-right-now-nestle-wants-a-bigger-slice-of-the-pie/25189/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PFE) Novartis Sees Profits In Alcon &#8211; Why You Should Too</title>
		<link>http://www.stockbloghub.com/2010/01/12/pfe-novartis-sees-profits-in-alcon-why-you-should-too/24802</link>
		<comments>http://www.stockbloghub.com/2010/01/12/pfe-novartis-sees-profits-in-alcon-why-you-should-too/24802#comments</comments>
		<pubDate>Wed, 13 Jan 2010 06:06:22 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACL]]></category>
		<category><![CDATA[Alcon Inc]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=24802</guid>
		<description><![CDATA[Tony Daltorio, Investment U Research Tuesday, January 12, 2010 Back in October, I wrote about how pharmaceutical companies captured the financial world’s attention with a myriad of lucrative mergers and acquisitions last year. Some of the more memorable deals included Pfizer Inc. (NYSE: PFE) snatching up Wyeth Labs in January for $68 billion and Johnson &#38; Johnson (NYSE: JNJ) purchasing Cougar Biotech in May for $1 billion. Not to be left out, Novartis ADR (NYSE: NVS) announced its own intentions in April to purchase eye care company Alcon (NYSE: ACL) for $50 billion last year. But Novartis apparently doesn’t want to be associated with its competitors, so it staunchly denies that the deal has anything to do with combating falling drug discovery rates or looming patent expirations. Chairman and CEO ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/12/pfe-novartis-sees-profits-in-alcon-why-you-should-too/24802/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(KFT) Kraft Foods Offers More Cash for Cadbury</title>
		<link>http://www.stockbloghub.com/2010/01/05/kft-kraft-foods-offers-more-cash-for-cadbury/24191</link>
		<comments>http://www.stockbloghub.com/2010/01/05/kft-kraft-foods-offers-more-cash-for-cadbury/24191#comments</comments>
		<pubDate>Tue, 05 Jan 2010 22:41:48 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Consumer Goods]]></category>
		<category><![CDATA[Food - Major Diversified]]></category>
		<category><![CDATA[ACL]]></category>
		<category><![CDATA[Alcon Inc]]></category>
		<category><![CDATA[Cadbury plc]]></category>
		<category><![CDATA[CBY]]></category>
		<category><![CDATA[KFT]]></category>
		<category><![CDATA[Kraft Foods Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=24191</guid>
		<description><![CDATA[Kraft Foods (KFT) has agreed to sell its North American pizza business to Nestle for $3.7 billion in cash. The transaction is expected to close in 2010. The sale includes the DiGiorno, Tombstone and Jack&#8217;s brands in the U.S., the Delissio brand in Canada and the California Pizza Kitchen trademark license. It also includes two manufacturing facilities in Medford and Little Chute, Wisconsin and the right to take on the leases for the pizza depots and delivery trucks. The pizza business is estimated to have generated 2009 net revenues of $1.6 billion. Nestle could fund this acquisition with the proceeds from the recent sale of its stake in eye-care company Alcon Inc. (ACL) to Swiss drug maker Novartis AG (NVS) for $28.1 billion in cash. Kraft said that it would ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/05/kft-kraft-foods-offers-more-cash-for-cadbury/24191/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(NVS) Novartis Announces Intent to Gain Full Ownership of Alcon</title>
		<link>http://www.stockbloghub.com/2010/01/05/nvs-novartis-announces-intent-to-gain-full-ownership-of-alcon/24126</link>
		<comments>http://www.stockbloghub.com/2010/01/05/nvs-novartis-announces-intent-to-gain-full-ownership-of-alcon/24126#comments</comments>
		<pubDate>Tue, 05 Jan 2010 18:54:16 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACL]]></category>
		<category><![CDATA[Alcon Inc]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=24126</guid>
		<description><![CDATA[Novartis (NVS) has recently announced that it intends to gain full ownership of eye care company Alcon Inc. (ACL). Novartis will first complete its April 2008 agreement with Nestlé S.A. whereby it will acquire a majority stake (77%) in Alcon. Of this, Novartis acquired a 25% stake in Alcon in 2008 for $10.4 billion. Novartis will be paying $28.1 billion for Nestlé’s remaining 52% stake in Alcon. Once this deal is completed in the second half of the year, Novartis is planning to acquire the remaining 23% minority stake in Alcon. Each Alcon share will receive 2.8 shares of Novartis. Novartis intends to fund its acquisition of the 52% stake in Alcon through available funds and external financing. Novartis’ outlay for acquiring a 77% stake in Alcon comes to about ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/05/nvs-novartis-announces-intent-to-gain-full-ownership-of-alcon/24126/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(RX) Big Pharma and Biotech &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2009/11/09/rx-big-pharma-and-biotech-industry-outlook/20146</link>
		<comments>http://www.stockbloghub.com/2009/11/09/rx-big-pharma-and-biotech-industry-outlook/20146#comments</comments>
		<pubDate>Mon, 09 Nov 2009 23:57:38 +0000</pubDate>
		<dc:creator>Shawn</dc:creator>
				<category><![CDATA[Research Services]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[ACL]]></category>
		<category><![CDATA[ACOR]]></category>
		<category><![CDATA[Acorda Therapeutics Inc]]></category>
		<category><![CDATA[Alcon Inc]]></category>
		<category><![CDATA[Alkermes]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[IMS Health Inc.]]></category>
		<category><![CDATA[Inc.]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MannKind Corporation]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MNKD]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[RX]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[Schering-Plough Corporation]]></category>
		<category><![CDATA[SGP]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[WYE]]></category>
		<category><![CDATA[Wyeth]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=20146</guid>
		<description><![CDATA[The pharmaceutical industry has witnessed major changes in 2009. Performance has been affected by factors like sluggish prescription trends, intensifying generic competition and limited phase III catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. According to IMS Health (RX), this is the main reason why global pharmaceutical market growth will be restricted to the mid-single digits through 2013. Over the next five years, products that currently generate about $137 billion in sales are expected to face generic competition Incorporatedluding Lipitor, Plavix and Seretide. At the same time, new products are not expected to generate the same level of sales as the products losing patent protection have. With most of the big pharma companies already facing patent challenges for their ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/09/rx-big-pharma-and-biotech-industry-outlook/20146/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ACL) Alcon Continues to Grow Pipeline</title>
		<link>http://www.stockbloghub.com/2009/10/26/acl-alcon-continues-to-grow-pipeline/18787</link>
		<comments>http://www.stockbloghub.com/2009/10/26/acl-alcon-continues-to-grow-pipeline/18787#comments</comments>
		<pubDate>Mon, 26 Oct 2009 23:34:30 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACL]]></category>
		<category><![CDATA[Advanced Micro Devices Inc.]]></category>
		<category><![CDATA[AGN]]></category>
		<category><![CDATA[Alcon Inc]]></category>
		<category><![CDATA[Allergan Inc.]]></category>
		<category><![CDATA[AMD]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=18787</guid>
		<description><![CDATA[Alcon, Inc. (ACL) recently entered into an in-licensing agreement with Potentia Pharmaceuticals, a privately-held biotechnology company that focuses on the development of medicines for the treatment of age-related macular degeneration (AMD). Alcon gained the right to develop Potentia&#8217;s leading drug candidate, POT-4, for the treatment of AMD. Alcon also gained the right to acquire Potentia’s shares on the achievement of certain development milestones and if Alcon opts to continue with the development of POT-4. Alcon will make upfront payments to Potentia for the initial license and option rights. Potentia is also entitled to receive future payments based on the achievement of several clinical and global regulatory approval milestones for different therapeutic indications and on Alcon&#8217;s decision to proceed with development. Potentia will also receive royalties based on sales of any ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/26/acl-alcon-continues-to-grow-pipeline/18787/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

